Medical Manager
Resume:
Shao Ning Yang M.S.
**** **** **. ***# **, Rego Park, NY 11374
Phone: 917-***-****
Email: **********@*****.***
Summary:
* ***** ** ******** **********.
• 8 years of animal model experience, including xenograft mouse models, drug testing, breeding and
colony maintenance.
• 5 years of cell-based drug testing experience.
• 2 years of experience in High Throughput Screening of candidate drugs for lymphoma eradication.
• Team leader and coordinator among teams.
Experience:
Weill Cornell Medical College October 2011- present
Department of Medicine, Division of Hematology and Oncology
Laboratory of Dr. Leandro Cerchietti
Research Associate, Lab Manager
• Managed and coordinated the set-up of the new lab, including organization of space, equipment, personnel,
databases and access to school resources.
• Ordering and organizing reagents and consumables.
• Interviewing, training and managing new and visiting lab personnel.
• Independently designing and performing experiments for the following projects:
• Regulation of mRNA stability and translatability during the germinal center reaction and lymphomagenesis.
• Cell metabolism and global metabolomics in lymphomas and metastatic solid tumors.
• Prognostic and predictive markers in Diffuse Large B Cell Lymphoma (DLBCL) and Follicular Lymphoma
patients.
Weill Cornell Medical College October 2010- October 2011
Department of Medicine, Division of Hematology and Oncology
Laboratory of Dr. Ari Melnick
Specialist
Independently performing experiments in project:
• Role of the stress response in the physiology of germinal centers and lymphomagenesis.
• Cell reprogramming and experimental pharmacology in lymphomas including combinatorial regimens.
Weill Cornell Medical College April 2008- October 2010
Department of Medicine, Division of Hematology and Oncology
Laboratory of Dr. Ari Melnick
Technician
Independently performing experiments in project:
• High throughput screening of therapeutic small molecules in DLBCL.
• Transcriptional and epigenetic programming in normal and malignant B-cells.
• Targeting heat shock protein-90 in DLBCL using several small molecules.
Albert Einstein College of Medicine October 2007- April 2008
Department of Medicine, Division of Hematology and Oncology
Laboratory of Dr. Ari Melnick
Technician
Independently performing experiments in project:
• Targeting transcription factor B-cell lymphoma-6 in DLBCL using peptidomimetic inhibitor.
Techniques:
Molecular Biology: DNA and RNA extraction, PCR, RT-PCR, Real-Time PCR, Southern blotting, DNA sequencing.
Cell Biology: Protein expression, protein extraction, western blotting, electrophoretic mobility shift assay, gel overlap assay, immunoprecipitation, chromatin immunoprecipitation, immunofluorescence, immunohistochemistry, cell culture, cell viability assay, ELISA, transfection of siRNA and/or plasmid.
Animal models: Drug testing in xenografted mice, mice breeding.
High Throughput Screening: Small molecules, drugs and chemical compounds.
Computer skill: MS-Office, Adobe Photoshop, ImageJ, Compusyn.
Publications:
DNA methyltransferase 1 and DNA methylation patterning contribute to germinal center B-cell differentiation.
Shaknovich R, Cerchietti L, Tsikitas L, Kormaksson M, De S, Figueroa ME, Ballon G, Yang SN, Weinhold N, Reimers M, Clozel T, Luttrop K, Ekstrom TJ, Frank J, Vasanthakumar A, Godley LA, Michor F, Elemento O, Melnick A. Blood. 2011 Sep 29;118(13):3559-69.
Inhibition of anaplastic lymphoma kinase (ALK) activity provides a therapeutic approach for CLTC-ALK-positive human diffuse large B cell lymphomas. Cerchietti L, Damm-Welk C, Vater I, Klapper W, Harder L, Pott C, Yang SN, Reiter A, Siebert R, Melnick A, Woessmann W. PLoS One. 2011 Apr 8;6(4):e18436.
BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy. Cerchietti LC, Hatzi K, Caldas-Lopes E, Yang SN, Figueroa ME, Morin RD, Hirst M, Mendez L, Shaknovich R, Cole PA, Bhalla K, Gascoyne RD, Marra M, Chiosis G, Melnick A. J Clin Invest. 2010 Nov 1. doi:pii: 42869. 10.1172/JCI42869.
A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. Cerchietti LC, Ghetu AF, Zhu X, Da Silva GF, Zhong S, Matthews M, Bunting KL, Polo JM, Farès C, Arrowsmith CH, Yang SN, Garcia M, Coop A, Mackerell AD Jr, Privé GG, Melnick A. Cancer Cell. 2010 Apr 13;17(4):400-11.
A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas. Cerchietti LC, Lopes EC, Yang SN, Hatzi K, Bunting KL, Tsikitas LA, Mallik A, Robles AI, Walling J, Varticovski L, Shaknovich R, Bhalla KN, Chiosis G, Melnick A. Nat Med. 2009 Dec;15(12):1369-76.
The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL. Ci W, Polo JM, Cerchietti L, Shaknovich R, Wang L, Yang SN, Ye K, Farinha P, Horsman DE, Gascoyne RD, Elemento O, Melnick A. Blood. 2009 May 28;113(22):5536-48.
A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo. Cerchietti LC, Yang SN, Shaknovich R, Hatzi K, Polo JM, Chadburn A, Dowdy SF, Melnick A. Blood. 2009 Apr 9;113(15):3397-405.
Education:
National Taiwan University, Institute of Biochemical Sciences, Taipei City, Taiwan June 2000
Master of Biochemical Sciences
National Central University, Taoyuan, Taiwan June 1998
Bachelor of Chemical Engineering
References: Leandro Cerchietti, MD
Raymond and Beverly Sackler Scholar
Assistant Professor
Hematology and Oncology Division
Medicine Department
Weill Cornell Medical College
Cornell University
1300 York Ave, C-620D, BOX 113
New York, NY 10021
Phone: 212-***-****
E-mail *******@***.*******.***
Ari Melnick, MD
Professor
Departments of Medicine and Pharmacology
Director, Sackler Center for Biomedical and Physical Sciences
Weill Cornell Medical College
Cornell University
1300 York Ave, C-620B, BOX 113
New York, NY 10021
Phone: 212-***-****
E-mail *******@***.*******.***
Maria E. Figueroa, MD
Assistant Professor
University of Michigan,
Department of Pathology,
109 Zina Pitcher Place,
Lab: BSRB 2348,
Office: BSRB 2019,
Ann Arbor, MI 48109-2200,
Office Phone: 734-***-****
E-mail ********@***.*****.***
Contact this candidate